Table 5 Oncolytic viruse for antitumor immunotherapy in clinical trials
From: Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy
Virus | Name | Modification | Tumor type | Phase | Effect | Identifier |
|---|---|---|---|---|---|---|
Adenovirus | DNX-2401 | Δ24-RGD insertion | Glioblastoma | Done | Enhancing immune response and prolonging patient survival | NCT00805376 |
H101 | E1B deletion, partial E3 deletion | Hepatocellular carcinoma, Pancreatic ductal adenocarcinoma | III/I | No results posted | NCT03780049 NCT05303090 | |
Enadenotucirev (ColoAd1) | Chimeric Ad11/3 group B | Resectable colon, bladder, Non-small cell lung cancer, renal cell carcinoma | I | Driving an immune response and tolerating enadenotucirev | NCT02053220 | |
CG0070 | E3 deletion; GM-CSF insertion | None muscular invasive bladder cancer | III | No results posted | NCT04452591 | |
Herpesvirus | T-VEC | ICP34.5 deletion, US11 deletion, GM-CSF insertion | Melanoma, soft tissue sarcoma | II | No results posted | NCT03555032 NCT04599062 |
HF10 | UL56 deletion, selected for single copy of UL52 | Refractory head and neck cancer, squamous cell carcinoma, skin Carcinoma of the breast, malignant melanoma | I | No results posted | NCT01017185 NCT02428036 | |
HSV-1716 | ICP34.5 deletion | Malignant pleural mesothelioma | II | No results posted | NCT01721018 | |
Vaccinia virus | PexaVec (JX594) | GM-CSF insertion, TK disruption | Primary or metastatic hepatic carcinoma | I | No regrowth of the tumor site occurred in all patients | NCT00629759 |
rVV-740CTA | Cancer testis antigen (CTA) epitopes, CD80 and CD154(40 L) expression | Breast carcinoma | I | No results posted | NCT03110445 | |
GL-ONC1 | TK disruption, haemagglutin disruption, F14.5 L disruption | Peritoneal carcinomatosis | II | Lysis of tumor cells and weak adverse reactions | NCT01443260 | |
Measles virus | MV-NIS | Edmonston vaccine measles strain; insertion of sodium-iodide symporter | Recurrent ovarian, primary peritoneal or fallopian tube cancer | II | No results posted | NCT02068794 |
Reovirus | Reolysin | None | Metastatic breast cancer | II | Significantly longer overall survival in the combination tharapy | NCT01656538 |
Coxsackie virus | Cavatak | Wild -type coxsackievirus A21 | Non-muscle invasive bladder cancer | I | Tumor cell death, enhancing immune responses | NCT02316171 |
